Combination of selective androgen and estrogen receptor modulators in orchiectomized rats.
Bone
Muscle
Orchiectomized rat model
Selective androgen receptor modulators (SARMs)
Selective estrogen receptor modulators (SERMs)
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
02
02
2022
accepted:
22
03
2022
pubmed:
17
4
2022
medline:
14
7
2022
entrez:
16
4
2022
Statut:
ppublish
Résumé
Selective androgen and estrogen receptor modulators, ostarine (OST) and raloxifen (RAL), reportedly improve muscle tissue and offer therapeutic approaches to muscle maintenance in the elderly. The present study evaluated the effects of OST and RAL and their combination on musculoskeletal tissue in orchiectomized rats. Eight-month-old Sprague Dawley rats were analyzed. Experiment I: (1) Untreated non-orchiectomized rats (Non-ORX), (2) untreated orchiectomized rats (ORX), (3) ORX rats treated with OST during weeks 0-18 (OST-P), (4) ORX rats treated with OST during weeks 12-18 (OST-T). Experiment II: 1) Non-ORX, (2) ORX, 3) OST-P, (4) ORX rats treated with RAL, during weeks 0-18 (RAL-P), 5) ORX rats treated with OST + RAL, weeks 0-18 (OST + RAL-P). The average daily doses of OST and RAL were 0.4 and 7 mg/kg body weight (BW). Weight, fiber size, and capillarization of muscles, gene expression, serum markers and the lumbar vertebral body were analyzed. OST-P exerted favorable effects on muscle weight, expression of myostatin and insulin growth factor-1, but increased prostate weight. OST-T partially improved muscle parameters, showing less effect on the prostate. RAL-P did not show anabolic effects on muscles but improved body constitution by reducing abdominal area, food intake, and BW. OST + RAL-P had an anabolic impact on muscle, reduced androgenic effect on the prostate, and normalized food intake. OST and RAL improved osteoporotic bone. The OST + RAL treatment appeared to be a promising option in the treatment of androgen-deficient conditions and showed fewer side effects than the respective single treatments.
Identifiants
pubmed: 35429299
doi: 10.1007/s40618-022-01794-7
pii: 10.1007/s40618-022-01794-7
pmc: PMC9270269
doi:
Substances chimiques
Androgens
0
Estrogen Receptor Modulators
0
Selective Estrogen Receptor Modulators
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1555-1568Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : DFG SE 1966/6-1
Organisme : Deutsche Forschungsgemeinschaft
ID : KO 4646/3-1
Informations de copyright
© 2022. The Author(s).
Références
Giannoulis MG, Martin FC, Nair KS, Umpleby AM, Sonksen P (2012) Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev 33(3):314–377. https://doi.org/10.1210/er.2012-1002
doi: 10.1210/er.2012-1002
pubmed: 22433122
pmcid: 5393154
Huang L-T, Wang J-H (2021) The therapeutic intervention of sex steroid hormones for sarcopenia. Front Med. https://doi.org/10.3389/fmed.2021.739251
doi: 10.3389/fmed.2021.739251
pubmed: 34792736
pmcid: 8302972
Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M (2012) The role of androgens and estrogens on healthy aging and longevity. J Gerontol A 67(11):1140–1152. https://doi.org/10.1093/gerona/gls068
doi: 10.1093/gerona/gls068
Barbonetti A, D’Andrea S, Francavilla S (2020) Testosterone replacement therapy. Andrology 8(6):1551–1566. https://doi.org/10.1111/andr.12774
doi: 10.1111/andr.12774
pubmed: 32068334
Palacios S, Mejias A (2015) An update on drugs for the treatment of menopausal symptoms. Expert Opin Pharmacother 16(16):2437–2447. https://doi.org/10.1517/14656566.2015.1085508
doi: 10.1517/14656566.2015.1085508
pubmed: 26395223
Stuenkel CA (2015) Menopausal hormone therapy: current considerations. Endocrinol Metab Clin N Am 44(3):565–585. https://doi.org/10.1016/j.ecl.2015.05.006
doi: 10.1016/j.ecl.2015.05.006
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, I. Writing Group for the Women’s Health Initiative (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333
doi: 10.1001/jama.288.3.321
Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT (2006) Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2(3):146–159. https://doi.org/10.1038/ncpendmet0120
doi: 10.1038/ncpendmet0120
pubmed: 16932274
pmcid: 2072878
Christiansen AR, Lipshultz LI, Hotaling JM, Pastuszak AW (2020) Selective androgen receptor modulators: the future of androgen therapy? Transl Androl Urol 9(Suppl 2):S135–S148. https://doi.org/10.21037/tau.2019.11.02
doi: 10.21037/tau.2019.11.02
pubmed: 32257854
pmcid: 7108998
Dorchies OM, Reutenauer-Patte J, Dahmane E, Ismail HM, Petermann O, Patthey- Vuadens O, Comyn SA, Gayi E, Piacenza T, Handa RJ, Decosterd LA, Ruegg UT (2013) The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy. Am J Pathol 182(2):485–504. https://doi.org/10.1016/j.ajpath.2012.10.018
doi: 10.1016/j.ajpath.2012.10.018
pubmed: 23332367
Wu B, Shah SN, Lu P, Bollinger LE, Blaeser A, Sparks S, Harper AD, Lu QL (2018) Long-term treatment of tamoxifen and raloxifene alleviates dystrophic phenotype and enhances muscle functions of FKRP dystroglycanopathy. Am J Pathol 188(4):1069–1080. https://doi.org/10.1016/j.ajpath.2017.12.011
doi: 10.1016/j.ajpath.2017.12.011
pubmed: 29571322
Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT (2016) Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep 18(6):37. https://doi.org/10.1007/s11912-016-0522-0
doi: 10.1007/s11912-016-0522-0
pubmed: 27138015
pmcid: 4853438
Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS (2011) The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2(3):153–161. https://doi.org/10.1007/s13539-011-0034-6
doi: 10.1007/s13539-011-0034-6
pubmed: 22031847
pmcid: 3177038
Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS (2013) Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 14(4):335–345. https://doi.org/10.1016/S1470-2045(13)70055-X
doi: 10.1016/S1470-2045(13)70055-X
pubmed: 23499390
pmcid: 4898053
Roch PJ, Henkies D, Carstens JC, Krischek C, Lehmann W, Komrakova M, Sehmisch S (2020) Ostarine and ligandrol improve muscle tissue in an ovariectomized rat model. Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2020.556581
doi: 10.3389/fendo.2020.556581
Duschek EJ, Gooren LJ, Netelenbos C (2004) Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol 150(4):539–546. https://doi.org/10.1530/eje.0.1500539
doi: 10.1530/eje.0.1500539
pubmed: 15080785
Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R (2004) Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res 19(9):1518–1524. https://doi.org/10.1359/JBMR.040503
doi: 10.1359/JBMR.040503
pubmed: 15312253
Jacobsen DE, Samson MM, Emmelot-Vonk MH, Verhaar HJ (2010) Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, double-blind, placebo-controlled trial. Eur J Endocrinol 162(2):371–376. https://doi.org/10.1530/EJE-09-0619
doi: 10.1530/EJE-09-0619
pubmed: 19884264
Cheung AS, Zajac JD, Grossmann M (2014) Muscle and bone effects of androgen deprivation therapy: current and emerging therapies. Endocr Relat Cancer 21(5):R371–R394. https://doi.org/10.1530/ERC-14-0172
doi: 10.1530/ERC-14-0172
pubmed: 25056176
Kamel HK, Maas D, Duthie EH Jr (2002) Role of hormones in the pathogenesis and management of sarcopenia. Drugs Aging 19(11):865–877. https://doi.org/10.2165/00002512-200219110-00004
doi: 10.2165/00002512-200219110-00004
pubmed: 12428995
Furuya K, Yamamoto N, Ohyabu Y, Morikyu T, Ishige H, Albers M, Endo Y (2013) Mechanism of the tissue-specific action of the selective androgen receptor modulator S-101479. Biol Pharm Bull 36(3):442–451. https://doi.org/10.1248/bpb.b12-00885
doi: 10.1248/bpb.b12-00885
pubmed: 23449329
Stuermer EK, Sehmisch S, Tezval M, Tezval H, Rack T, Boekhoff J, Wuttke W, Herrmann TR, Seidlova-Wuttke D, Stuermer KM (2009) Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats. World J Urol 27(4):547–555. https://doi.org/10.1007/s00345-009-0373-5
doi: 10.1007/s00345-009-0373-5
pubmed: 19221760
pmcid: 2720581
Komrakova M, Rechholtz C, Pohlmann N, Lehmann W, Schilling AF, Wigger R, Sehmisch S, Hoffmann DB (2019) Effect of alendronate or 8-prenylnaringenin applied as a single therapy or in combination with vibration on muscle structure and bone healing in ovariectomized rats. Bone Rep. https://doi.org/10.1016/j.bonr.2019.100224
doi: 10.1016/j.bonr.2019.100224
pubmed: 31909095
pmcid: 6940722
Brancaccio P, Maffulli N, Limongelli FM (2007) Creatine kinase monitoring in sport medicine. Br Med Bull 81–82:209–230. https://doi.org/10.1093/bmb/ldm014
doi: 10.1093/bmb/ldm014
pubmed: 17569697
Andersen P (1975) Capillary density in skeletal muscle of man. Acta Physiol Scand 95(2):203–205. https://doi.org/10.1111/j.1748-1716.1975.tb10043.x
doi: 10.1111/j.1748-1716.1975.tb10043.x
pubmed: 127508
Horak V (1983) A successive histochemical staining for succinate dehydrogenase and “reversed”-ATPase in a single section for the skeletal muscle fibre typing. Histochemistry 78(4):545–553
doi: 10.1007/BF00496207
Peter JB, Barnard RJ, Edgerton VR, Gillespie CA, Stempel KE (1972) Metabolic profiles of three fiber types of skeletal muscle in guinea pigs and rabbits. Biochemistry 11(14):2627–2633
doi: 10.1021/bi00764a013
Armstrong RB, Phelps RO (1984) Muscle fiber type composition of the rat hindlimb. Am J Anat 171(3):259–272. https://doi.org/10.1002/aja.1001710303
doi: 10.1002/aja.1001710303
pubmed: 6517030
Staron RS, Kraemer WJ, Hikida RS, Fry AC, Murray JD, Campos GE (1999) Fiber type composition of four hindlimb muscles of adult Fisher 344 rats. Histochem Cell Biol 111(2):117–123. https://doi.org/10.1007/s004180050341
doi: 10.1007/s004180050341
pubmed: 10090572
Schwartz-Giblin S, Rosello L, Pfaff DW (1983) A histochemical study of lateral longissimus muscle in rat. Exp Neurol 79(2):497–518. https://doi.org/10.1016/0014-4886(83)90229-7
doi: 10.1016/0014-4886(83)90229-7
pubmed: 6217980
Saul D, Harlas B, Ahrabi A, Kosinsky RL, Hoffmann DB, Wassmann M, Wigger R, Boker KO, Sehmisch S, Komrakova M (2018) Effect of strontium ranelate on the muscle and vertebrae of ovariectomized rats. Calcif Tissue Int 102(6):705–719. https://doi.org/10.1007/s00223-017-0374-0
doi: 10.1007/s00223-017-0374-0
pubmed: 29242963
Spandidos A, Wang X, Wang H, Seed B (2010) PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res 38:D792–D799. https://doi.org/10.1093/nar/gkp1005
doi: 10.1093/nar/gkp1005
pubmed: 19906719
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262
doi: 10.1006/meth.2001.1262
pubmed: 11846609
Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS (1997) Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138(11):4613–4621. https://doi.org/10.1210/endo.138.11.5496
doi: 10.1210/endo.138.11.5496
pubmed: 9348186
Saul D, Gleitz S, Nguyen HH, Kosinsky RL, Sehmisch S, Hoffmann DB, Wassmann M, Menger B, Komrakova M (2017) Effect of the lipoxygenase-inhibitors baicalein and zileuton on the vertebra in ovariectomized rats. Bone. https://doi.org/10.1016/j.bone.2017.04.011
doi: 10.1016/j.bone.2017.04.011
pubmed: 28455215
Seibel MJ (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26(4):97–122
pubmed: 16648882
pmcid: 1320175
Komrakova M, Nagel J, Hoffmann DB, Lehmann W, Schilling AF, Sehmisch S (2020) Effect of selective androgen receptor modulator enobosarm on bone healing in a rat model for aged male osteoporosis. Calcif Tissue Int. https://doi.org/10.1007/s00223-020-00751-x
doi: 10.1007/s00223-020-00751-x
pubmed: 32876707
pmcid: 7593387
Antonio J, Wilson JD, George FW (1999) Effects of castration and androgen treatment on androgen-receptor levels in rat skeletal muscles. J Appl Physiol (1985) 87(6):2016–2019. https://doi.org/10.1152/jappl.1999.87.6.2016
doi: 10.1152/jappl.1999.87.6.2016
Dubois V, Simitsidellis I, Laurent MR, Jardi F, Saunders PT, Vanderschueren D, Claessens F (2015) Enobosarm (GTx-024) modulates adult skeletal muscle mass independently of the androgen receptor in the satellite cell lineage. Endocrinology 156(12):4522–4533. https://doi.org/10.1210/en.2015-1479
doi: 10.1210/en.2015-1479
pubmed: 26393303
Vyskocil F, Gutmann E (1977) Anabolic effect of testosterone on the levator ani muscle of the rat. Pflugers Arch 371(1–2):3–8. https://doi.org/10.1007/BF00580765
doi: 10.1007/BF00580765
pubmed: 145581
Dillon EL, Durham WJ, Urban RJ, Sheffield-Moore M (2010) Hormone treatment and muscle anabolism during aging: androgens. Clin Nutr 29(6):697–700. https://doi.org/10.1016/j.clnu.2010.03.010
doi: 10.1016/j.clnu.2010.03.010
pubmed: 20452103
pmcid: 2964430
Komrakova M, Hoffmann DB, Nuehnen V, Stueber H, Wassmann M, Wicke M, Tezval M, Stuermer KM, Sehmisch S (2016) The effect of vibration treatments combined with teriparatide or strontium ranelate on bone healing and muscle in ovariectomized rats. Calcif Tissue Int 99(4):408–422. https://doi.org/10.1007/s00223-016-0156-0
doi: 10.1007/s00223-016-0156-0
pubmed: 27272029
Shen HH, Yang CY, Kung CW, Chen SY, Wu HM, Cheng PY, Lam KK, Lee YM (2019) Raloxifene inhibits adipose tissue inflammation and adipogenesis through Wnt regulation in ovariectomized rats and 3 T3–L1 cells. J Biomed Sci 26(1):62. https://doi.org/10.1186/s12929-019-0556-3
doi: 10.1186/s12929-019-0556-3
pubmed: 31470850
pmcid: 6717377
Seidlová-Wuttke D, Stürmer KM, Stürmer EK, Sehmisch S, Wuttke W (2006) Contrasting effects of estradiol, testosterone and of a black cohosh extract on density, mechanical properties and expression of several genes in the metaphysis of the tibia and on fat tissue of orchidectomized rats. Maturitas 55:S64–S74. https://doi.org/10.1016/j.maturitas.2006.06.018
doi: 10.1016/j.maturitas.2006.06.018
Neubauer BL, Best KL, Clemens JA, Gates CA, Goode RL, Jones CD, Laughlin ME, Shaar CJ, Toomey RE, Hoover DM (1993) Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat. Prostate 23(3):245–262. https://doi.org/10.1002/pros.2990230307
doi: 10.1002/pros.2990230307
pubmed: 8234067
Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT (2003) Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 304(3):1334–1340. https://doi.org/10.1124/jpet.102.040840
doi: 10.1124/jpet.102.040840
pubmed: 12604714
Jones A, Hwang DJ, Narayanan R, Miller DD, Dalton JT (2010) Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology 151(8):3706–3719. https://doi.org/10.1210/en.2010-0150
doi: 10.1210/en.2010-0150
pubmed: 20534726
Sarchielli E, Comeglio P, Filippi S, Cellai I, Guarnieri G, Guasti D, Rapizzi E, Rastrelli G, Bani D, Vannelli G, Vignozzi L, Morelli A, Maggi M (2020) Testosterone improves muscle fiber asset and exercise performance in a metabolic syndrome model. J Endocrinol 245(2):259–279. https://doi.org/10.1530/JOE-19-0532
doi: 10.1530/JOE-19-0532
pubmed: 32134722
Komrakova M, Werner C, Wicke M, Nguyen BT, Sehmisch S, Tezval M, Stuermer KM, Stuermer EK (2009) Effect of daidzein, 4-methylbenzylidene camphor or estrogen on gastrocnemius muscle of osteoporotic rats undergoing tibia healing period. J Endocrinol 201(2):253–262. https://doi.org/10.1677/JOE-08-0521
doi: 10.1677/JOE-08-0521
pubmed: 19273502
Schiefer S (2018) Einfluss der Ganzkörpervibration in Kombination mit Östrogen und Raloxifen auf die Skelettmuskulatur der ovarektomierten Ratte (Influence of whole-body vibration in combination with estrogen and raloxifene on the skeletal muscles of the ovariectomized rat). Klinik für Unfallchirurgie, Orthopädie und Plastische Chirurgie. Universität Göttingen Medizinische Fakultät, Göttingen, p 97
Wagner PD (2011) The critical role of VEGF in skeletal muscle angiogenesis and blood flow. Biochem Soc Trans 39(6):1556–1559. https://doi.org/10.1042/BST20110646
doi: 10.1042/BST20110646
pubmed: 22103486
Jasuja R, LeBrasseur NK (2014) Regenerating skeletal muscle in the face of aging and disease. Am J Phys Med Rehabil 93(11 Suppl 3):S88-96. https://doi.org/10.1097/PHM.0000000000000118
doi: 10.1097/PHM.0000000000000118
pubmed: 24879554
Roth SM, Walsh S (2004) Myostatin: a therapeutic target for skeletal muscle wasting. Curr Opin Clin Nutr Metab Care 7(3):259–263. https://doi.org/10.1097/00075197-200405000-00004
doi: 10.1097/00075197-200405000-00004
pubmed: 15075916
Shao R, Ljungstrom K, Weijdegard B, Egecioglu E, Fernandez-Rodriguez J, Zhang FP, Thurin-Kjellberg A, Bergh C, Billig H (2007) Estrogen-induced upregulation of AR expression and enhancement of AR nuclear translocation in mouse fallopian tubes in vivo. Am J Physiol Endocrinol Metab 292(2):E604–E614. https://doi.org/10.1152/ajpendo.00350.2006
doi: 10.1152/ajpendo.00350.2006
pubmed: 17047162
Dieli-Conwright CM, Spektor TM, Rice JC, Todd Schroeder E (2009) Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells. Acta Physiol (Oxf) 197(3):187–196. https://doi.org/10.1111/j.1748-1716.2009.01997.x
doi: 10.1111/j.1748-1716.2009.01997.x
Hoffmann DB, Komrakova M, Pflug S, von Oertzen M, Saul D, Weiser L, Walde TA, Wassmann M, Schilling AF, Lehmann W, Sehmisch S (2019) Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis. J Bone Miner Metab 37(2):243–255. https://doi.org/10.1007/s00774-018-0929-9
doi: 10.1007/s00774-018-0929-9
pubmed: 29785666
Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT (2007) Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res 24(2):328–335. https://doi.org/10.1007/s11095-006-9152-9
doi: 10.1007/s11095-006-9152-9
pubmed: 17063395
Komrakova M, Furtwangler J, Hoffmann DB, Lehmann W, Schilling AF, Sehmisch S (2020) The selective androgen receptor modulator ostarine improves bone healing in ovariectomized rats. Calcif Tissue Int 106(2):147–157. https://doi.org/10.1007/s00223-019-00613-1
doi: 10.1007/s00223-019-00613-1
pubmed: 31531719
Migliaccio S, Brama M, Spera G (2007) The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging 2(1):55–64. https://doi.org/10.2147/ciia.2007.2.1.55
doi: 10.2147/ciia.2007.2.1.55
pubmed: 18044075
pmcid: 2684086
Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20(11):1905–1911. https://doi.org/10.1359/JBMR.050714
doi: 10.1359/JBMR.050714
pubmed: 16234962
Lin Y, Liu LJ, Murray T, Sodek J, Rao L (2004) Effect of raloxifene and its interaction with human PTH on bone formation. J Endocrinol Invest 27(5):416–423. https://doi.org/10.1007/BF03345284
doi: 10.1007/BF03345284
pubmed: 15279072
Canpolat S, Tug N, Seyran AD, Kumru S, Yilmaz B (2010) Effects of raloxifene and estradiol on bone turnover parameters in intact and ovariectomized rats. J Physiol Biochem 66(1):23–28. https://doi.org/10.1007/s13105-010-0008-8
doi: 10.1007/s13105-010-0008-8
pubmed: 20428990
Moe SM (2008) Disorders involving calcium, phosphorus, and magnesium. Prim Care 35(2):215–237. https://doi.org/10.1016/j.pop.2008.01.007
doi: 10.1016/j.pop.2008.01.007
pubmed: 18486714
pmcid: 2486454
Komulainen J, Kytola J, Vihko V (1994) Running-induced muscle injury and myocellular enzyme release in rats. J Appl Physiol 77(5):2299–2304. https://doi.org/10.1152/jappl.1994.77.5.2299
doi: 10.1152/jappl.1994.77.5.2299
pubmed: 7868448